On September 30, 2020, the Third Circuit reversed a decision by the Eastern District of Pennsylvania ordering AbbieVie, Inc. (“AbbieVie”) and Besins Healthcare Inc. (“Besins”) to pay $448 million in disgorgement of ill-gotten profits for allegedly filing sham patent lawsuits to stifle competition. AbbieVie and Besins had filed patent infringement lawsuits against two developers of generic alternatives to its brand-name testosterone gel product AndroGel. The FTC sued AbbieVie and Besins in 2014 alleging that the patent suits were baseless and brought for no other ...
Blog Editors
Recent Updates
- Maryland Legislature Slashes Child Victims Act Damages Cap by More than 50%
- Master the First Moves in Litigation for Courtroom Advantage – Speaking of Litigation Video Podcast
- Medicaid Fraud Recoveries Top More Than $1 Billion in 2024—But Will the Big Beautiful Bill Impact Those Numbers in 2025?
- ACLU Sues Tennessee Over Immigration Law Making it a Felony to Vote for Sanctuary City Policies
- Term Ends with Major Decisions, Including Banning Universal Injunctions - SCOTUS Today